Pharmacokinetic determinants of hydroxychloroquine whole-blood exposure in Chinese patients with systemic lupus erythematosus: a population modeling study based on real-world therapeutic drug monitoring

Introduction Hydroxychloroquine (HCQ) is a cornerstone therapy for systemic lupus erythematosus (SLE), yet marked interindividual variability in whole‐blood exposure complicates therapeutic drug monitoring (TDM). This study aimed to characterize pharmacokinetic determinants of HCQ exposure in Chinese patients with SLE using real‐world TDM data. Methods This single‐center observational study included 580 patients contributing 872 whole‐blood HCQ concentrations during long‐term maintenance treatment. Population pharmacokinetic (PopPK) analysis was performed using nonlinear mixed‐effects modeling under presumed steady‐state conditions with nominal dosing‐interval assignments. A one‐compartment model with first-order absorption was used, with the absorption rate constant and apparent volume of distribution fixed to literature‐informed values. Covariates were evaluated stepwise, and model performance was assessed using goodness‐of‐fit diagnostics, bootstrap analysis, visual predictive checks, and fixed‐parameter sensitivity analysis. Results The typical apparent clearance (CL/F) was 23.862 L/h. Body weight and sex were retained as covariates on CL/F, although the sex‐related association remains provisional given the predominantly female cohort and potential unmeasured confounding, including medication adherence. Age, estimated glomerular filtration rate (eGFR), and albumin were not retained as additional covariates. Model diagnostics showed no apparent systematic bias, and the directions of retained covariate effects were preserved across alternative fixed‐parameter assumptions. Discussion The model provides a pharmacokinetic framework for interpreting HCQ exposure during maintenance treatment under presumed steady‐state conditions. Independent external validation and studies incorporating clinical efficacy and safety outcomes are needed before the model can support therapeutic target definition or individualized dosing.

Authors

Institutions

Publication Details

Journal
Frontiers in Pharmacology
Published
2026-11-17
DOI
https://doi.org/10.3389/fphar.2026.1984722
Primary Topic
Systemic Lupus Erythematosus Research
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Pharmacokinetic determinants of hydroxychloroquine whole-blood exposure in Chinese patients with systemic lupus erythematosus: a population modeling study based on real-world therapeutic drug monitoring

Han Xie, Zijing Zhao, Ao Shen, Wenxi Xie et al.
2 links
Frontiers in Pharmacology
Systemic Lupus Erythematosus Research
article

Pharmacokinetic determinants of hydroxychloroquine whole-blood exposure in Chinese patients with systemic lupus erythematosus: a population modeling study based on real-world therapeutic drug monitoring

Han Xie, Zijing Zhao, Ao Shen, Wenxi Xie, Qiong Zhang, Qing Shu, Shuang Wang
article en

Abstract

Introduction Hydroxychloroquine (HCQ) is a cornerstone therapy for systemic lupus erythematosus (SLE), yet marked interindividual variability in whole‐blood exposure complicates therapeutic drug monitoring (TDM). This study aimed to characterize pharmacokinetic determinants of HCQ exposure in Chinese patients with SLE using real‐world TDM data. Methods This single‐center observational study included 580 patients contributing 872 whole‐blood HCQ concentrations during long‐term maintenance treatment. Population pharmacokinetic (PopPK) analysis was performed using nonlinear mixed‐effects modeling under presumed steady‐state conditions with nominal dosing‐interval assignments. A one‐compartment model with first-order absorption was used, with the absorption rate constant and apparent volume of distribution fixed to literature‐informed values. Covariates were evaluated stepwise, and model performance was assessed using goodness‐of‐fit diagnostics, bootstrap analysis, visual predictive checks, and fixed‐parameter sensitivity analysis. Results The typical apparent clearance (CL/F) was 23.862 L/h. Body weight and sex were retained as covariates on CL/F, although the sex‐related association remains provisional given the predominantly female cohort and potential unmeasured confounding, including medication adherence. Age, estimated glomerular filtration rate (eGFR), and albumin were not retained as additional covariates. Model diagnostics showed no apparent systematic bias, and the directions of retained covariate effects were preserved across alternative fixed‐parameter assumptions. Discussion The model provides a pharmacokinetic framework for interpreting HCQ exposure during maintenance treatment under presumed steady‐state conditions. Independent external validation and studies incorporating clinical efficacy and safety outcomes are needed before the model can support therapeutic target definition or individualized dosing.

Frontiers in PharmacologyVol. 17
Nanjing University of Chinese Medicine (CN), China Pharmaceutical University (CN), Nanjing Drum Tower Hospital (CN)
Good health and well-being
Systemic Lupus Erythematosus Research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon